Literature DB >> 30529036

A tetrameric form of CD40 ligand with potent biological activities in both mouse and human primary B cells.

Nannan Lai1, Qing Min1, Ermeng Xiong1, Jun Liu1, Lumin Zhang1, Shoya Yasuda2, Ji-Yang Wang3.   

Abstract

CD40 ligand (CD40 L) expressed by activated T cells interacts with CD40 on B cells and triggers B cell survival, proliferation and differentiation. Deficiency in CD40 L or CD40 in humans causes hyper IgM syndrome due to a defect in T-B interaction that is essential for Ig gene class switch recombination (CSR). CD40 L belongs to the tumor necrosis factor family and normally forms a homotrimer on the cell surface, which is important for its biological activity. To generate a multimeric CD40 L that can be used to stimulate both mouse and human B cells, we fused the extracellular domain of mouse CD40 L, which is known to also bind human CD40, with streptavidin (SA) that forms a stable tetramer under physiological conditions. As expected, 293 T cells transiently transfected with an SA-CD40 L expression vector secreted tetrameric SA-CD40 L in the culture supernatant. The secreted SA-CD40 L exhibited > 25-fold stronger activities in inducing the survival, activation and proliferation of both mouse and human primary B cells than did an agonistic anti-mouse or anti-human CD40 antibody. In the presence of IL-4, SA-CD40 L also induced efficient CSR and plasma cell differentiation in both mouse and human B cells. Moreover, administration of SA-CD40 L in mice induced activation and proliferation of spleen B cells in vivo. These results demonstrate that the SA-CD40 L fusion protein generated in the present study recapitulates the function of membrane-bound trimeric CD40 L and has potent biological activities in both mouse and human primary B cells.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  B cell activation; CD40L; Ig gene class switch recombination; Streptavidin; Tetramer

Mesh:

Substances:

Year:  2018        PMID: 30529036     DOI: 10.1016/j.molimm.2018.11.018

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  3 in total

1.  Concepts for agonistic targeting of CD40 in immuno-oncology.

Authors:  David M Richards; Julian P Sefrin; Christian Gieffers; Oliver Hill; Christian Merz
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

Review 2.  Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity.

Authors:  You Qin; Furong Lu; Kexing Lyu; Alfred E Chang; Qiao Li
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

3.  Cellular Mechanisms Underlying B Cell Abnormalities in Patients With Gain-of-Function Mutations in the PIK3CD Gene.

Authors:  Wenjie Wang; Qing Min; Nannan Lai; Krisztian Csomos; Ying Wang; Luyao Liu; Xin Meng; Jinqiao Sun; Jia Hou; Wenjing Ying; Qinhua Zhou; Bijun Sun; Xiaoying Hui; Boglarka Ujhazi; Sumai Gordon; David Buchbinder; Catharina Schuetz; Manish Butte; Jolan E Walter; Xiaochuan Wang; Ji-Yang Wang
Journal:  Front Immunol       Date:  2022-06-21       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.